Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Univesity of Iowa Hospital and Clinics, Iowa City, Iowa Duke University Health System, Durham, North Carolina